AR022017A1 - Un agente para tratar el trastorno de la funcion de las celulas visuales. el metodo de tratamiento y el uso de dicho agente para la produccion de unacomposicion farmaceutica - Google Patents

Un agente para tratar el trastorno de la funcion de las celulas visuales. el metodo de tratamiento y el uso de dicho agente para la produccion de unacomposicion farmaceutica

Info

Publication number
AR022017A1
AR022017A1 ARP990106748A ARP990106748A AR022017A1 AR 022017 A1 AR022017 A1 AR 022017A1 AR P990106748 A ARP990106748 A AR P990106748A AR P990106748 A ARP990106748 A AR P990106748A AR 022017 A1 AR022017 A1 AR 022017A1
Authority
AR
Argentina
Prior art keywords
agent
treatment
disorder
treat
production
Prior art date
Application number
ARP990106748A
Other languages
English (en)
Original Assignee
Sucampo Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sucampo Pharmaceuticals Inc filed Critical Sucampo Pharmaceuticals Inc
Publication of AR022017A1 publication Critical patent/AR022017A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se revela un agente para el tratamiento del trastorno de la funcion de las células visuales que contiene un inhibidor de interleucina 2 tal como uncompuesto macrolido, particularmente FK506. Se describe además, el uso de dicho inhibidor para la preparacion de composiciones farmacéuticas.
ARP990106748A 1998-12-24 1999-12-23 Un agente para tratar el trastorno de la funcion de las celulas visuales. el metodo de tratamiento y el uso de dicho agente para la produccion de unacomposicion farmaceutica AR022017A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11393998P 1998-12-24 1998-12-24

Publications (1)

Publication Number Publication Date
AR022017A1 true AR022017A1 (es) 2002-09-04

Family

ID=22352417

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP990106748A AR022017A1 (es) 1998-12-24 1999-12-23 Un agente para tratar el trastorno de la funcion de las celulas visuales. el metodo de tratamiento y el uso de dicho agente para la produccion de unacomposicion farmaceutica

Country Status (13)

Country Link
EP (1) EP1140134A1 (es)
JP (1) JP2002542150A (es)
KR (1) KR20010099928A (es)
CN (1) CN1224420C (es)
AR (1) AR022017A1 (es)
AU (1) AU781049B2 (es)
BR (1) BR9917113A (es)
CA (1) CA2356382A1 (es)
MX (1) MXPA01006449A (es)
NO (1) NO20013146L (es)
NZ (1) NZ513111A (es)
TW (1) TW546145B (es)
WO (1) WO2000038703A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070032853A1 (en) 2002-03-27 2007-02-08 Hossainy Syed F 40-O-(2-hydroxy)ethyl-rapamycin coated stent
AU2003209297A1 (en) 2002-01-18 2003-09-02 Massachusetts Eye And Ear Infirmary Methods and compositions for preserving the viability of photoreceptor cells
ES2428354T3 (es) * 2002-09-18 2013-11-07 Trustees Of The University Of Pennsylvania Rapamicina para usar en la inhibición o prevención de la neovascularización coroidea
US20050118344A1 (en) 2003-12-01 2005-06-02 Pacetti Stephen D. Temperature controlled crimping
JP2007505932A (ja) 2003-09-18 2007-03-15 マクサイト， インコーポレイテッド 経強膜送達
WO2006086750A1 (en) 2005-02-09 2006-08-17 Macusight, Inc. Liquid formulations for treatment of diseases or conditions
US7592330B2 (en) 2005-08-08 2009-09-22 Massachusetts Eye And Ear Infirmary Methods and compositions for preserving the viability of photoreceptor cells
US8492400B2 (en) 2006-02-09 2013-07-23 Santen Pharmaceutical Co., Ltd. Stable formulations, and methods of their preparation and use
CN101443004B (zh) 2006-03-23 2013-03-06 参天制药株式会社 用于与血管通透性有关的疾病或病症的制剂
EP3868407A4 (en) * 2018-10-15 2022-02-23 Osaka University MEDICATIONS FOR IMPROVING OR PREVENTING SYMPTOMS RELATED TO RETINA AND/OR PHOTORECEPTION AND METHODS OF SCREENING OF AN AGENT TO IMPROVE SYMPTOMS RELATED TO RETINA AND/OR PHOTORECEPTION

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE147936T1 (de) * 1990-08-23 1997-02-15 Univ New York Verfahren und zusammensetzungen für die behandlung durch t-zellen vermittelter krankheiten
IL102414A (en) * 1991-07-25 1996-08-04 Univ Louisville Res Found Medicinal preparations for the treatment of ocular inflammation, containing rapamycin
US5922773A (en) * 1992-12-04 1999-07-13 The Children's Medical Center Corp. Glaucoma treatment
US5597809A (en) * 1994-06-23 1997-01-28 Massachusetts Eye & Ear Infirmary Treatment of optic neuritis
JP2002511868A (ja) * 1997-06-30 2002-04-16 アラーガン・セイルズ・インコーポレイテッド 増殖性硝子体網膜症を治療するためのカルシウム遮断薬
CZ287497B6 (cs) * 1997-12-30 2000-12-13 Galena, A. S. Topické oční přípravky s imunosupresivními látkami
US6376517B1 (en) * 1998-08-14 2002-04-23 Gpi Nil Holdings, Inc. Pipecolic acid derivatives for vision and memory disorders

Also Published As

Publication number Publication date
EP1140134A1 (en) 2001-10-10
CN1352565A (zh) 2002-06-05
MXPA01006449A (es) 2002-04-24
WO2000038703A1 (en) 2000-07-06
CN1224420C (zh) 2005-10-26
NO20013146D0 (no) 2001-06-22
AU781049B2 (en) 2005-05-05
CA2356382A1 (en) 2000-07-06
KR20010099928A (ko) 2001-11-09
NO20013146L (no) 2001-08-20
AU1690600A (en) 2000-07-31
TW546145B (en) 2003-08-11
JP2002542150A (ja) 2002-12-10
BR9917113A (pt) 2001-10-23
NZ513111A (en) 2003-10-31

Similar Documents

Publication Publication Date Title
ES2128552T3 (es) Combinacion de un inhibidor de la biosintesis del colesterol y un inhibidor de la absorcion del colesterol beta-lactama.
MX9202407A (es) Composicion farmaceutica que contiene un compuesto de alilamina como el agente activo y proceso para su preparacion.
ECSP941104A (es) Derivados de 2,6 diaminopurina, procedimiento para su preparacion y composiciones farmaceuticas que los contienen
AR009457A1 (es) Inhibidores de metaloproteasa heterociclica y uso de la misma para preparar composiciones farmaceuticas.
AR007827A1 (es) 3-ureido-piridofuranos y -piridotiofenos, procedimiento para su preparacion, composicion que los comprende y uso de dichos compuestos para lapreparacion de medicamentos.
ATE370730T1 (de) Pharmazeutische zubereitungen, die chelatbildner/sequestriermittel enthalten und deren dermatologische verwendung
CO5160320A1 (es) Metodos y composiciones para la prevencion de tolerancia a medicamentos das.
BR0111206A (pt) Derivados de arilmetilamina para uso como inibidores de triptase
ES2044912T3 (es) Composiciones farmaceuticas dotadas de actividad secuestrante para los acidos biliares, conteniendo colestiramina como principio activo, y procedimiento para su preparacion.
YU186291A (sh) Novi derivati hidroksamske kiseline i n-hidroksikarbamida
ES2176502T3 (es) Derivados de hidroxilamina utiles para mejorar la pproduccion de chaperonas moleculares su su preparacion.
AR003427A1 (es) Péptidos relacionados con dolastatina, procedimiento para prepararlos, composiciones farmacéuticas que los contienen y el uso de los mismos para la preparación de dichas composiciones farmacéuticas.
AR018357A1 (es) Acido petroselinico en una composicion y en un metodo para reducir o eliminar la irritacion o la picazon de la piel inducida por los alfa-hidroxiacidos
AU7023987A (en) Pharmaceutical compositions containing propylene glycol and/or polyethylene glycol and urea as active main components and use thereof
AR023807A1 (es) Un agente para tratar el ojo seco y el uso de un compuesto macrolido para preparar composiciones farmaceuticas para el tratamiento del ojo seco
ES2052603T3 (es) Derivados de bencimidazol, procedimiento para su produccion y composicion farmaceutica que los contienen.
BR9507730A (pt) Uso de formulações em gel como composições de tratamento
BR0311460A (pt) Composição farmacêutica de liberação modificada, uso de uma formulação, e, método para tratar um distúrbio cardiovascular em um paciente
BRPI0407652A (pt) método para acentuar a eficácia de um agente ativo, composição e método para produzir a composição
HUP9602498A2 (hu) Antimikrobiális hatású gyógyászati készítmények
BR0109672A (pt) Uso de zd6126 ou de um seu sal farmaceuticamente aceitável e um de: um agente antitumoral de plantina e um taxano, composição farmacêutica, produto de combinação, kit, e, método para a produção de um efeito de danificação vascular em um animal de sangue quente
DE69919597D1 (de) Topische formulierungen, die hautpenetrations-mittel enthalten, und ihre verwendung
CO5050343A1 (es) Combinacion de fentolamina y apomorfina para el tratamiento de la funcion y disfuncion sexual humana
AR028987A1 (es) Compuesto derivado de ciclopentapiridin-cetona, composicion farmaceutica que lo contiene y su uso en la fabricacion de un medicamento util para tratar una enfermedad
BR9917113A (pt) Agente para tratar de distúrbio de função de células visuais compreendendo um inibidor de interleucina 2, seu método de tratamento e uso

Legal Events

Date Code Title Description
FA Abandonment or withdrawal